Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2020

View Archived Issues

Tau keeps gliomas in check

AVETUX trial shows potential of avelumab and cetuximab with FOLFOX in colorectal cancer

Janssen Biotech describes new STING agonists

Cav3.2 blockers patented by Nippon Chemiphar and Kindai University

HEXAPharmatec discovers new catechol derivatives

Curis and Aurigene amend their collaboration agreement for CA-170

Positive update for phase I/IIa study of OpRegen in dry AMD

Karuna Therapeutics updates research and discovery efforts in CNS

Novan gives update on the phase III B-SIMPLE program of SB-206

Phase I data for magrolimab plus avelumab regimen in ovarian cancer

AVN-576 shows promise in rat models of TBI

Sino announces IND filing for TDI-01 for fibrosis

Phase I results for troriluzole plus nivolumab in patients advanced or refractory solid tumors

Pan-Cancer Project looks closer, sees more

Genentech describes new NLRP3 inflammasome inhibitors

Inhibition of HSP90A, a potential strategy to combat NANOG+ immune-refractory tumors

Low dose eRapa safe and well-tolerated in prostate cancer patients

Phase III trial of Fintepla in Lennox-Gastaut syndrome meets primary endpoint

Boehringer Ingelheim studies BI-905681 in phase I for advanced, unresectable or metastatic tumors

Adial initiates pivotal phase III trial of AD-04 for alcohol use disorder

Kleo obtains IND clearance to study KP-1237 in combination with NK cells for multiple myeloma

Betta Pharmaceuticals patents PD-1/PD-L1 interaction inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...